RPID
Rapid Micro Biosystems, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Rapid Micro Biosystems, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
No changes.
No changes.
No thesis.
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Rapid Micro Biosystems, Inc.
0.73
+0.02 · +3.17%
post 0.71 −1.81%
Same SIC code · 6
Same SEC industry code: Agilent Technologies, Inc., Waters Corp, Mettler Toledo International Inc/ and 3 more; no measured co-movers for Rapid Micro Biosystems, Inc..
Same SIC code · 6
Same SEC industry code: Agilent Technologies, Inc., Waters Corp, Mettler Toledo International Inc/ and 3 more; no measured co-movers for Rapid Micro Biosystems, Inc..
| Manager | Value | % base | |
|---|---|---|---|
| Bain Capital Life Sciences Investors | $14.6M | 48.13% | 0.00% |
| Armistice Capital | $5.8M | 18.99% | new |
| ABG-WTT Global Life Science Capital Partners GP | $3.2M | 10.55% | 0.00% |
| Vanguardindex-like | $1.7M | 5.60% | −0.05% |
| Evernest Financial | $875,380 | 2.89% | +16.99% |
| Manager | Value | % base | |
|---|---|---|---|
| Bain Capital Life Sciences Investors | $14.6M | 48.13% | 0.00% |
| Armistice Capital | $5.8M | 18.99% | new |
| ABG-WTT Global Life Science Capital Partners GP | $3.2M | 10.55% | 0.00% |
| Vanguardindex-like | $1.7M | 5.60% | −0.05% |
| Evernest Financial | $875,380 | 2.89% | +16.99% |
Bull2
Bear2